Gestrinone (cas 16320-04-0) versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study*
-
Add time:08/06/2019 Source:sciencedirect.com
ObjectivesTo evaluate the efficacy of Gestrinone (cas 16320-04-0) versus leuprolide acetate (LA) in improving pelvic pain in women with endometriosis and to compare their effects on bone mineral density and serum lipid profile.
We also recommend Trading Suppliers and Manufacturers of Gestrinone (cas 16320-04-0). Pls Click Website Link as below: cas 16320-04-0 suppliers
Prev:Gestrinone (cas 16320-04-0) versus danazol as preoperative treatment for hysteroscopic surgery: a prospective, randomized evaluation
Next:Gestrinone (cas 16320-04-0) inhibits macrophage function and mitogen-stimulated lymphocyte proliferation in vitro) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Endometrial patterns during therapy with danazol or Gestrinone (cas 16320-04-0) for endometriosis: Structural and ultrastructural study08/09/2019
- Individual and combined effects of triptoreline and Gestrinone (cas 16320-04-0) on experimental endometriosis in rats08/08/2019
- Gestrinone (cas 16320-04-0) inhibits macrophage function and mitogen-stimulated lymphocyte proliferation in vitro08/07/2019
- Gestrinone (cas 16320-04-0) versus danazol as preoperative treatment for hysteroscopic surgery: a prospective, randomized evaluation08/05/2019
- Gestrinone (cas 16320-04-0) inhibits growth of human uterine leiomyoma may relate to activity regulation of ERα, Src and P38 MAPK08/04/2019
- Mechanism of emergency contraception with Gestrinone (cas 16320-04-0): a preliminary investigation08/03/2019
- Enzyme-linked immunosorbent assays for the synthetic steroid Gestrinone (cas 16320-04-0)08/02/2019
